Study Sample Collection Protocol for “Analysis by EarlyGuard™ of Serum miRNA from Women Referred for Additional Testing Due to Abnormal Breast Imaging Classified as BI-RADS® 3, 4 or 5”
By drawing a tube of blood, data is obtained that will hopefully improve the breast cancer screening process in the future. Researchers are looking at serum miRNA signatures to determine if a subsequent breast biopsy has a higher likelihood of being positive or negative. This study is recruiting patients have breast imaging studies suspicious for cancer discovered during screening.
Tina Fortney, RN, BSN, CCRC: 425.688.5407, Tina.Fortney@overlakehospital.org
Hania Shakalia, CRC, 425.635.6082, Hania.Shakalia@overlakehospital.org
Pooja Rajeevan, CRC: 425.635.6081, Pooja.Rajeevan@overlakehospital.org
Clinical Trial Categories